145 results
8-K
NAOV
NanoVibronix Inc
9 Apr 24
NanoVibronix Issues Letter to Stockholders
4:05pm
the materials attached hereto.
The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished pursuant
8-K
NAOV
NanoVibronix Inc
28 Mar 24
NanoVibronix Signs Agreement for Research and Development of Next Generation PainShield and UroShield
9:09am
into the Agreement which is attached hereto as Exhibit 99.1. The Company undertakes no obligation to update, supplement or amend the materials
DEFA14A
6bal6eoks7wzqmcj
29 Nov 23
Additional proxy soliciting materials
8:43pm
8-K
u4d9a7 9tu2
28 Nov 23
NanoVibronix Announces Agreement for Clinical Study of UroShield at the University of Michigan
9:00am
8-K
kpwax1a 635ui
14 Nov 23
NanoVibronix Issues Letter to Shareholders
12:00am
8-K
6fojf4rcld0hvara46cs
7 Nov 23
Receives Stocking Order from U.K. Distribution Partner in Anticipation of Increasing Demand
8:30am
8-K
r8ua hpc5
27 Sep 23
NanoVibronix Gains Approval for Inclusion of UroShield Products in NHS Prescription Services’ Drug Tariff
8:00am
D
lkmm9ulr
13 Sep 23
$13.55 mm in equity / options / securities to be acquired, sold $13.55 mm, 1 investor
4:45pm
8-K
1eaqabdcs n9
6 Sep 23
NanoVibronix Announces Presentation of Positive Independent Testing Results of UroShield at ICS Annual Meeting
8:30am
8-K
EX-10.1
iz1aiag0mqwa4e4qj
1 Sep 23
NanoVibronix Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
4:30pm
8-K
EX-10.2
knna0o8xremlz
1 Sep 23
NanoVibronix Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
4:30pm
8-K
yk4e3 ekuqmn4
30 Aug 23
NanoVibronix Cites Positive Results from Independent Testing of UroShield
8:30am
8-K
zm78 nk6up4
29 Aug 23
Regulation FD Disclosure
4:05pm
8-K
0n4k8e2m9eporyaa4
28 Aug 23
NanoVibronix Applies for Inclusion of UroShield Products in NHS Prescription Services’ Drug Tariff
8:30am